Thomas Powles
St Bartholomew's Hospital(GB)Queen Mary University of London(GB)Royal Free London NHS Foundation Trust(GB)Barts Health NHS Trust(GB)The Royal Free Hospital(GB)Cancer Research UK(GB)Cancer Research UK(GB)London Cancer(GB)University College London(GB)
Publications by Year
Research Areas
Bladder and Urothelial Cancer Treatments, Cancer Immunotherapy and Biomarkers, Urinary and Genital Oncology Studies, Renal cell carcinoma treatment, Cancer Genomics and Diagnostics
Most-Cited Works
- → MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer(2014)2,412 cited
- → Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial(2016)2,185 cited
- → Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma(2021)1,691 cited
- → Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma(2021)1,675 cited
- → Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma(2020)1,442 cited
- → Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial(2017)1,399 cited